)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
CytomX Therapeutics (CTMX) investor relations material
CytomX Therapeutics Morgan Stanley 23rd Annual Global Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Morgan Stanley 23rd Annual Global Healthcare Conference summary10 Sep, 2025
Platform and pipeline overview
Focus on oncology biologics using a proprietary Probody Therapeutic Platform, which employs antibody masking to improve the therapeutic window for potent anti-cancer agents.
Two lead clinical programs: CX-2051 (EPCAM-targeted masked ADC) and CX-801 (masked interferon alpha 2B).
Masking technology enables targeting of tumor-specific protease activity, activating drugs locally in cancer tissue and reducing off-target toxicity.
EPCAM is a highly expressed, stable antigen in colorectal cancer (CRC), making it an attractive, broadly applicable target.
No patient selection for EPCAM expression required, supporting an all-comer approach in CRC.
Clinical data and safety profile
Phase 1 CX-2051 study in late-line CRC showed a 28% objective response rate and 94% disease control rate in heavily pretreated patients.
Progression-free survival reached 5.8 months, outperforming current fourth-line standards (PFS 3.5–3.7 months, ORR 1–2%).
Safety profile is favorable: no dose-limiting toxicities, manageable hematologic effects, and GI toxicity consistent with TOPO-1 inhibitors.
Masking strategy appears effective, with no observed pancreatic or liver toxicity, differentiating from prior EPCAM-targeted agents.
One grade 5 adverse event (GI toxicity leading to kidney injury in a patient with a solitary kidney) was deemed an outlier; study continues with enhanced monitoring.
Development plans and future directions
Three expansion cohorts (7.2, 8.6, 10 mg/kg) fully enrolled; 70+ patient data update expected in Q1 2026, with six months' follow-up for most.
Next steps include dose selection based on response, PFS, and adverse event analysis, with a randomized study against standard of care planned for 2026.
Combination studies with bevacizumab and chemotherapy are planned to move CX-2051 into earlier CRC treatment lines.
Broader development aims for pan-tumor applications, leveraging EPCAM’s expression in multiple solid tumors.
CX-801 phase 1 in melanoma progressing, with translational biomarker data expected in Q4 and combination data with Keytruda planned for 2026.
How will Q1 2026 data guide 2051 dose?
2051 registrational pathway for accelerated approval?
What is the value of CX-801 Q4 biomarker data?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next CytomX Therapeutics earnings date
Q3 20256 Nov, 2025
Next CytomX Therapeutics earnings date
Q3 20256 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
)
Edge19 Sep 2025
American Express: An Empire of Plastic
How history, brand, and structure have steadily built American Express' moat, and why Warren Buffett still calls it a one-of-a-kind business.
Frequently asked questions
CytomX Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer treatments. The company utilizes its proprietary Probody® platform to create antibody-based therapies that target cancer cells while minimizing damage to healthy tissues. CytomX’s approach aims to improve the safety and effectiveness of existing cancer therapies by activating its drugs only in the tumor microenvironment. The company's development pipeline includes therapeutic candidates designed for a variety of cancers, with the goal of addressing unmet medical needs in oncology. The company is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage